Beyond BET proteins, inhibiting the EP300/CBP bromodomain (e.g., CCS1477 inhibitor) also represents a promising therapeutic avenue across various hematological malignancies (Nicosia et al., 2023). Here, DNER is linked to hematologic disorder.